TBPH
HEALTHCARETheravance Biopharma Inc
$16.94+0.21 (+1.26%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TBPH Today?
No stock-specific AI insight has been generated for TBPH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.33$21.03
$16.94
Fundamentals
Market Cap$873M
P/E Ratio8.2
EPS$2.06
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin1.0%
Debt / Equity—
Trading
Volume313K
Avg Volume (10D)—
Shares Outstanding51.5M
TBPH News
21 articles- TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline HurdleYahoo Finance·May 8, 2026
- Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Xencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook RaisedYahoo Finance·May 1, 2026
- Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)Yahoo Finance·Apr 24, 2026
- B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14Yahoo Finance·Apr 20, 2026
- Theravance Stock Declines Around 17% in Three Months: Here's WhyYahoo Finance·Apr 16, 2026
- Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo TherapeuticsYahoo Finance·Apr 6, 2026
- TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law FirmBenzinga·Apr 3, 2026
- 5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthYahoo Finance·Apr 2, 2026
- Theravance's Q4 Earnings and Revenues Miss EstimatesYahoo Finance·Mar 20, 2026
- All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong BuyYahoo Finance·Mar 20, 2026
- Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag EstimatesYahoo Finance·Mar 19, 2026
- Theravance Bio: Q4 Earnings SnapshotYahoo Finance·Mar 19, 2026
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 19, 2026
- Assertio (ASRT) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 16, 2026
- How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And CashYahoo Finance·Mar 11, 2026
- Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)Yahoo Finance·Mar 9, 2026
- Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)Yahoo Finance·Mar 6, 2026
- Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failureClinicaltrialsarena·Mar 4, 2026
- The Excruciating Failure That Could Prompt Theravance, Down 26%, To Sell ItselfYahoo Finance·Mar 3, 2026
All 21 articles loaded
Price Data
Open$16.78
Previous Close$16.73
Day High$17.05
Day Low$16.63
52 Week High$21.03
52 Week Low$8.33
52-Week Range
$8.33$21.03
$16.94
Fundamentals
Market Cap$873M
P/E Ratio8.2
EPS$2.06
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin1.0%
Debt / Equity—
Trading
Volume313K
Avg Volume (10D)—
Shares Outstanding51.5M
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—